Effect of Telitacicep combined with Methotrexate on the levels of rheumatoid factor and anti-cyclic citrullinated peptide antibody in patients with moderate-to-severe rheumatoid arthritis
10.13431/j.cnki.immunol.j.20250112
- VernacularTitle:泰它西普联合甲氨蝶呤对中重度类风湿关节炎患者类风湿因子、抗环瓜氨酸肽抗体水平的影响
- Author:
Hong HE
1
;
Feng CHEN
;
Bojin CHEN
Author Information
1. 青海大学附属医院风湿免疫科,西宁 810000
- Publication Type:Journal Article
- Keywords:
moderate-to-severe rheumatoid arthritis;
Telitacicept;
Methotrexate;
joint function;
rheumatoid factor;
anti-cyclic citrullinated peptide antibody
- From:
Immunological Journal
2025;41(11):813-818
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effect of Telitacicept combined with Methotrexate on the levels of rheumatoid factor(RF)and anti-cyclic citrullinated peptide(CCP)antibody in patients with moderate-to-severe rheumatoid arthritis(RA).Methods A total of 120 patients with moderate-to-severe RA diagnosed from January 2023 to January 2025 were selected and divided into the Telitacicept group(n=40),the Methotrexate group(n=40)and the combination group(n=40)by random number table method according to different treatment regimens.The Telitacicept group was treated with Telitacicept,the Methotrexate group was treated with Methotrexate,and the combination group was treated with Telitacicept combined with Methotrexate.The therapeutic effects,swollen joint count(SJC),tender joint count(TJC),the duration of morning stiffness,the Visual Analogue Scale(VAS)pain score,the clinical disease activity index(CDAI)score,the disease activity score in 28 joints(DAS28),the Health Assessment Questionnaire(HAQ)score,the erythrocyte sedimentation rate(ESR),as well as the levels of serum RF,anti-CCP antibody,C-reactive protein(CRP),and tumor necrosis factor-α(TNF-α)were compared among the three groups.The adverse reactions during the treatment period of the three groups were statistically compared.Results After treatment,the total effective rate of the combination group was 95.00%(38/40),which was higher than that of the Telitacicept group at 80.00%(32/40)and the Methotrexate group at 75.00%(30/40,P<0.05).After treatment,the SJC and TJC in the combination group were less than those in the Telitacicept group and the Methotrexate group,and the duration of morning stiffness was shorter than that in the Telitacicept group and the Methotrexate group;the VAS score,CDAI score,DAS28 score,HAQ score,ESR,as well as the levels of serum RF,anti-CCP antibody,CRP and TNF-α were lower than those in the Telitacicept group and the Methotrexate group(P<0.05).There was no statistical difference in the incidence of adverse reactions among the three groups(P>0.05).Conclusion Telitacicept combined with Methotrexate can improve the clinical efficacy and quality of life of patients with moderate-to-severe RA,effectively improve the levels of RF and anti-CCP antibodies,and has favorable safety profile.
